Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

I want to enter information about my cancer and treatments

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT02855944IIIRecurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsColorado, Georgia, Maine, Texas
Drug(s) in Trial Other Drug Names Main Known Action
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT02091141IIaAdvanced solid tumors with ALK mutations or high TMBMy Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These AgentsView DrugsArizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
AlectinibALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802ALK kinase inhibitor
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
NCT02584478IIaRecurrent ovarian cancerA Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)View DrugsCalifornia, Florida, Louisiana, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AnlotinibAL3818VEGFR2/3 kinase inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02419417IIaPlatinum resistant or refractory ovarian cancer with BRCA1/2-mutationsA Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic MalignanciesView DrugsCalifornia, Colorado, Oregon, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986158BET inhibitor BMS-986158BET inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02658890IIaAdvanced solid tumors (in expansion)A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsView DrugsArizona, California, Florida, Georgia, Illinois, Maryland, Michigan, Missouri, New Jersey, New York, Ohio, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986205Inhibits IDO1 to stimulate immune response
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02502266II/IIIPlatinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutant ovarian cancerA Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)View DrugsAlaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitor
NCT02272998IIAdvanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterationsPhase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)View DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
Ponatinibmultitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534Multi-targeted kinase inhibitor
NCT02079740IIAdvanced solid tumors with KRAS or NRAS mutations (in expansion)An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
NavitoclaxBcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263Bcl-2, Bcl-XL, and Bcl-w inhibitor
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitor
NCT01037790IIAdvanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterationsPhase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PalbociclibIbrance, PD0332991, PD-0332991CDK4/6 inhibitor
NCT01953926IIAdvanced solid tumors with activating HER2 mutationsAn Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.View DrugsArizona, California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
NeratinibHKI-272, PD272EGFR, HER2, HER4 kinase inhibitor
NCT02203513IIRecurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancerA Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
Prexasertibcheckpoint kinase 1 inhibitor LY2606368, LY2606368Chk1/2 inhibitor
NCT02312245IIPlatinum resistant or refractory ovarian cancerAvatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitor
NCT02485990IIPlatinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane)An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)View DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02693535IIOvarian Expansion for BRCA MUT1/2 or CDKN2A loss or mutation or Advanced solid tumors with molecular alterations in ALK, ROS1, MET, CDK4, CDK6, CSF1R, PDGFR, VEGFR, mTOR, TSC, ERBB2, BRAFV600E/D/K/R, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, ATM, POLD, POLE, high TMB, MSI high)Targeted Agent and Profiling Utilization Registry (TAPUR) StudyView DrugsAlabama, Arizona, California, Florida, Georgia, Illinois, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonist
CobimetinibCotellic, GDC-0973, XL518MEK1 inhibitor
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitor
DasatinibBMS-354825, SprycelSRC and bcr-abl kinase inhibitor
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
PalbociclibIbrance, PD0332991, PD-0332991CDK4/6 inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitor
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitor
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
TemsirolimusCCI-779, ToriselmTOR inhibitor
TrastuzumabHER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, HerceptinHER2 antagonist
VemurafenibRO5185426, PLX4032, ZelborafBRAF kinase inhibitor
NCT02465060IIAdvanced solid tumors with alterations in ALK, cKIT, EGFR, ERBB2 AMP, FGFR1-3, FGFR1-3 AMP, GNAQ, GNA11, MET, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, ROS1, SMO, TSC1/2Molecular Analysis for Therapy Choice (MATCH)View DrugsAlabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
AfatinibBIBW 2992 MA2, Gilotrif, Afatinib dimaleateEGFR, HER2, HER4 kinase inhibitor
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitor
Erdafitinibpan-FGFR tyrosine kinase inhibitor JNJ-42756493pan-FGFR kinase inhibitor
LarotrectinibTrk inhibitor LOXO-101Pan-Trk kinase inhibitor
OsimertinibTagrisso, AZD9291, EGFR inhibitor AZD9291, MereletinibEGFR kinase inhibitor
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitor
SapanisertibTAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128TORC1/2 kinase inhibitor
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitor
TrastuzumabHER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, HerceptinHER2 antagonist
VismodegibHedgehog antagonist GDC-0449, Erivedge, GDC-0449Smoothened antagonist
NCT02568267IIAdvanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangementsAn Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene RearrangementsView DrugsArizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101ALK, TRK, ROS1 kinase inhibitor
NCT01827384IIAdvanced solid tumors with mutations in BRAF, KRAS, NRAS, NF1, PIK3CA, AKT1, MTOR, FBXW7, PTEN, ATM, ATR, ERCC1, MLH1, MSH2, NBN, RAD51, PARP1/2,TP53Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid TumorsView DrugsColorado, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
EverolimusZortress, RAD001, Certican, AfinitormTOR inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitor
VeliparibABT-888PARP inhibitor
NCT02554812IIAdvanced solid tumors (in ovarian expansion)A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced MalignanciesView DrugsCalifornia, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
PD-0360324anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324CSF1R antagonist and tumor-associated macrophage inhibitor
PF-04518600anti-OX40 antibody PF-04518600Stimulates OX40 to increase T cell activation and immune response
NCT02832167IIAdvanced solid tumorsAn Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic MalignanciesView DrugsArizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02628067IIAdvanced solid tumors with high MSIA Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)View DrugsCalifornia, Colorado, Florida, Maryland, Massachusetts, Minnesota, New Jersey, New Mexico, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02576444IIAdvanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutationsA Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid TumorsView DrugsConnecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
AZD6738ATR kinase inhibitor
CapivasertibAkt inhibitor AZD5363pan-AKT inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02785250IIRecurrent ovarian cancerA Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian CancerView DrugsCalifornia, Georgia, New York, Oregon, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivin
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO1 to stimulate immune response
NCT01851369IIAdvanced solid tumors and granulosa cell ovarian cancer (in expansion)A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
methoxyamineTRC102Base excision repair inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
NCT02873975IIAdvanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutationsA Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair DeficiencyView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
Prexasertibcheckpoint kinase 1 inhibitor LY2606368, LY2606368Chk1/2 inhibitor
NCT02364713IIPlatinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
MV-NISoncolytic measles virus encoding thyroidal sodium iodide symporterInduces immune response and tumor cell lysis
NCT01697527IIAdvanced NY-ESO-1+ solid tumorsAdoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced MalignanciesView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
NY-ESO-1 reactive TCR retroviral vector transduced autologous PBLanti-NY-ESO-1 TCR gene-engineered lymphocytesImmune response against cancer expressing NY-ESO-1
NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccineImmune response against cancer expressing NY-ESO-1
NCT02834013IIAdvanced ovarian germ cell, mucinous, squamous cell, or adenocarcinomaDART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsView DrugsAlabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02900560IIPlatinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease)Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsCalifornia, Maryland, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
Oral AzacitidineCC-486DNA methylation inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02843165IIAdvanced solid tumors with lesion treatable with radiotherapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03026062IIPlatinum resistant or refractory ovarian cancerRandomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT03093155IIPlatinum resistant, refractory or persistent ovarian cancerA Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancersView DrugsConnecticut, Maryland
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
IxabepiloneAzaepothilone B, BMS-247550, epothilone B lactam, Epothilone-B, IxempraMicrotubule stabilizer/mitotic inhibitor
NCT02587598IIAdvanced solid tumors (in expansion)A Phase 1/2 Study of INCB053914 in Subjects With Advanced MalignanciesView DrugsArizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, Ohio, Oklahoma, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
Azacytidineazacitidine, Vidaza, Mylosar, 5-AZCDNA methylation inhibitor
INCB053914pan-PIM inhibitor INCB053914PIM1, 2, 3 inhibitor
NCT02920996IIAdvanced solid tumors with NTRK1-3 rearrangementsA Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK RearrangementsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
Merestinibc-Met inhibitor LY2801653, LY2801653Multi-targeted RTK inhibitor
NCT03113487IIPlatinum resistant ovarian cancer (<4 prior cytotoxic therapies)P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
p53MVAModified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53Immune response against p53 tumor antigen
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03212274IIAdvanced solid tumors with IDH1 or IDH2 mutationsA Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid TumorsView DrugsCalifornia, Connecticut, District of Columbia, Kentucky, Maryland, Massachusetts, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03253679IIAdvanced solid tumors with CCNE1 AMPA Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 AmplificationView DrugsCalifornia, Colorado, Florida, Kentucky, New York, North Carolina, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
NCT03274661IIAdvanced solid tumorsEvaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair DeficiencyView DrugsFlorida
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03284385IIAdvanced solid tumors with SETD2 deficiencyA Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesView DrugsCalifornia, District of Columbia, Maryland, Massachusetts, Missouri, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
NCT03300843IIAdvanced solid tumors (with resectable tumor)A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous CancerView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
Peptide loaded dendritic cell vaccineAnti-tumor immune response
NCT03310879IIAdvanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplificationsA Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6View DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitor
NCT03348631IIRecurrent or persistent endometrioid/clear cell ovarian cancerA Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial AdenocarcinomaView DrugsIllinois, Rhode Island
Drug(s) in Trial Other Drug Names Main Known Action
Tazemetostathistone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438EZH2 histone methyltransferase inhibitor
NCT03355976IIRecurrent clear cell ovarian cancerBrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasView DrugsRhode Island
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03342417IIPlatinum resistant or refractory ovarian cancerPhase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer PatientsView DrugsCalifornia, Georgia, Illinois, New York
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03147976IIAdvanced solid tumors with MET over-expression or mutationA Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) MutationsView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AMG 337c-Met kinase inhibitor
NCT03395080IIPlatinum resistant or refractory ovarian cancerA Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian CancerView DrugsAlabama, Arizona, Florida, Massachusetts, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
DKN-01DKK1-neutralizing monoclonal antibody DKN-01Dickkopf-1 (DKK1) antagonist
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03428802IIAdvanced solid tumors with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityView DrugsNew Jersey
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT01876511IIAdvanced solid tumors with positive MSI or tumors with negative MSI and high TMBPhase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) TumorsView DrugsCalifornia, Maryland, New York, Ohio, Oregon, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03570619IIAdvanced solid tumors with CDK12 alterationsIMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsView DrugsMichigan, New York
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03565991IIAdvanced solid tumors with BRCA1/2 or ATM mutationsA Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant TumorsView DrugsCalifornia, Georgia, Louisiana, Massachusetts, Missouri, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitor
NCT03579316IIRecurrent ovarian cancer (PD on or after prior PARP inhibitor)A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP InhibitionView DrugsMassachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03610490IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
MDA-TILautologous tumor-infiltrating lymphocytes MDA-TILAnti-tumor immune response
NCT03651271IIRecurrent ovarian cancer with high MSIAn Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerView DrugsCalifornia, Massachusetts, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03668119IIAdvanced solid tumors with high TMBA Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)View DrugsCalifornia, Colorado, Florida, Illinois, Indiana, Minnesota, New Jersey, New York, North Carolina, Oregon, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03587311IIPlatinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancerA Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian CancerView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
Anetumab ravtansineBAY 94-9343, Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343ADC: anti-mesothelin + microtubule destabilizer (DM4)
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03682289IIRecurrent ovarian cancerPhase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor MalignanciesView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03693014IIAdvanced solid tumors with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03718091IIAdvanced solid cancer with ATM truncation mutations or other HR gene mutationsA Phase II Study of M6620 (VX-970) in Selected Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
BerzosertibVX-970, M6620, VE-822, ATR kinase inhibitor VX-970ATR kinase inhibitor
NCT03673124IILow grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or PeritoneumView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
LetrozoleFemaraAromatase inhibitor
RibociclibKisqali, LEE011, CDK4/6 Inhibitor LEE011, KisqaliCDK4/6 inhibitor
NCT03461952IIAdvanced solid tumors with POLE and/or POLD1 mutationsA Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based AssayView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03776812IIPlatinum resistant or refractory ovarian cancerA Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsArizona, Illinois
Drug(s) in Trial Other Drug Names Main Known Action
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitor
RelacorilantCORT125134GR antagonist
NCT03836352IIEpithelial ovarian cancer (with tumor lesions < 5 cm)A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.View DrugsNew York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivin
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03797326IIAdvanced solid tumorsA Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)View DrugsCalifornia, Colorado, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
LenvatinibE7080, ER-203492-00, LenvimaVEGFR1-3 kinase inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03868423IIAdvanced solid tumors with ALK or ROS1 activating genomic aberrationsPhase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 OncogenesView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
BrigatinibAP26113ALK and EGFR kinase inhibitor
NCT03834220IIAdvanced solid tumors with a FGFR1, FGFR2 or FGFR3 fusionA Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3View DrugsArizona, California, Florida, Louisiana, Maryland, Massachusetts, New Jersey, New York, North Carolina, Ohio, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
Debiopharm 1347CH5183284, FF284, FGFR Inhibitor Debio 1347FGFR1-3 inhibitor
NCT03697304IIAdvanced solid tumors with prior PD-1/PD-L1 targeted treatmentAn Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic TherapyView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
BI 754091anti-PD-1 monoclonal antibody BI 754091Blocks PD-L1/2 inhibition of T cells
BI 754111Blocks LAG-3 inhibition of T cells
NCT03684785Ib/IIAdvanced solid tumorsA Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid TumorsView DrugsCalifornia, Florida, Iowa, Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action
AST-008TLR9 agonist AST-008TLR agonist and immune cell stimulator
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03684811Ib/IIAdvanced solid tumors with IDH1 mutationsA Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 MutationView DrugsFlorida, Iowa, Michigan, New Jersey, Texas, Utah
Drug(s) in Trial Other Drug Names Main Known Action
FT-2102mutated IDH1 inhibitor
NCT03601897Ib/IIAdvanced solid tumorsAn Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid TumorsView DrugsAlabama, New York, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
Rebastinibmultitargeted tyrosine kinase inhibitor DCC-2036Multi-targeted kinase inhibitor
NCT02759588Ib/IIPlatinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease)Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)View DrugsCalifornia, Florida
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitor
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
GL-ONC1light-emitting oncolytic vaccinia virus GL-ONC1Membrane disrupter
Liposomal doxorubicinDoxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin HydrochlorideTopoisomerase II inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02606305Ib/IIAdvanced FRalpha+ ovarian cancerA Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube CancerView DrugsMassachusetts, Ohio, Oklahoma, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
Mirvetuximab SoravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)
NCT02551185IbAdvanced solid tumorsA Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
ACY-241HDAC inhibitor ACY-241, histone deacetylase inhibitor ACY-241HDAC inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03260322IbAdvanced solid tumorsA Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsView DrugsArizona, California, Florida, Iowa, Kansas, Michigan, New York, Pennsylvania, Tennessee, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
ASP8374PTZ-201Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03236935IbAdvanced solid tumors with high MSI or dMMRPhase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair Deficient CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
L-NMMApan-nitric oxide synthase inhibitor, NG-monomethyl-L-arginineNOS inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03113188IbAdvanced solid tumorsPhase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory TumorsView DrugsArizona, Louisiana, Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action
CBP501G2 checkpoint inhibitor CBP501G2 checkpoint inhibitor
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03239145IbAdvanced solid tumors (inc ovarian expansion)Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
TrebananibAMG 386Angiopoietin 1/2 antagonist
NCT03162562IbRecurrent or persistent ovarian cancerProspective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal OriginView DrugsFlorida, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
OregovomabOvaRex, Monoclonal Antibody B43.13, B43.13Immune response against cancer expressing CA125
poly ICLCpoly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLCActivates dendritic cells and induces interferon production
NCT02994953IbAdvanced solid tumorsA Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid TumorsView DrugsCalifornia, Connecticut, Florida, Louisiana, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
NHS-IL12M9241, immunocytokine NHS-IL12IL-12 receptor agonist
NCT03099174IbAdvanced solid tumorsAn Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts.View DrugsCalifornia, Connecticut, Minnesota, Nevada, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitor
XentuzumabBI-836845IGF-1/2 antagonist
NCT03611868IbAdvanced solid tumorsA Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid TumorsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
APG-115MDM2-p53 inhibitor APG-115, p53-HDM2 protein-protein interaction inhibitor APG-115MDM2 inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03586661IbRecurrent ovarian cancer with BRCA1/2 mutations (or high grade serous with BRCA1/2 WT)(inc expansion)A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
NiraparibMK4827, ZejulaPARP inhibitor
NCT03589651IbAdvanced solid tumors (inc expansion)A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsView DrugsCalifornia, Illinois, North Carolina, Pennsylvania, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO1 to stimulate immune response
INCB050465PI3K-delta inhibitor INCB050465PI3K delta inhibitor
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
NCT03621982IbAdvanced solid tumors (inc expansion)A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid TumorsView DrugsCalifornia, Connecticut, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Camidanlumab Tesirineanti-CD25-PBD antibody-drug conjugate ADCT-301, ADCT-301DNA damaging agent
NCT03650348IbAdvanced HER2+ solid tumors (inc expansion)A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid TumorsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Immune response against cancer expressing HER2
NCT03558139IbPlatinum resistant or refractory ovarian cancer (inc expansion)A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint Inhibitor Naïve Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum ChemotherapyView DrugsIllinois, Michigan, Oklahoma, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
Hu5F9-G4anti-CD47 monoclonal antibody Hu5F9-G4Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis
NCT02761694IbAdvanced solid tumors with AKT1/2/3, PI3K, or PTEN mutations (in expansion)A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN MutationsView DrugsOklahoma, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
ARQ 751pan-AKT inhibitor ARQ 751Akt inhibitor
FulvestrantFaslodex, ICI 182,780, ZD9238ER antagonist (SERD)
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03318445IbAdvanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
IrinotecanCamptosar, Campto, Campothecin-11Topoisomerase I inhibitor
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03307785IbAdvanced solid tumorsPhase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic CancerView DrugsArizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NiraparibMK4827, ZejulaPARP inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
TSR-022Blocks TIM-3 inhibition of T cells
TSR-042ANB011, anti-PD-1 monoclonal antibody TSR-042Blocks PD-L1/2 inhibition of T cells
NCT03168061IbAdvanced solid tumorsA Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaView DrugsCalifornia, Indiana, Missouri, Nevada, New York, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action
NC-6300epirubicin-incorporating micelle, epirubicin-conjugated polymer micelles, nanoparticle epirubicin, micellar nanoparticle-encapsulated epirubicin, K-912Topoisomerase II inhibitor
NCT03875313IbAdvanced solid tumorsA Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid TumorsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CB-839glutaminase inhibitor CB-839Glutaminase inhibitor
TalazoparibTalazoparib Tosylate, BMN-673, MDV3800PARP inhibitor
NCT03833427IbAdvanced solid tumorsA Phase 1b Multi-center Clinical Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors.View DrugsCalifornia, Michigan, New Jersey, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
SelumetinibAZD6244, ARRY-142886MEK inhibitor
NCT03449381Ia/IbAdvanced solid tumors (inc expansion)A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid TumorsView DrugsConnecticut, Florida, New York, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BI 907828MDM2 inhibitor
NCT03514121Ia/IbAdvanced solid tumors (in ovarian expansion)A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid TumorsView DrugsArizona, California, Connecticut, Illinois, Michigan, Oklahoma, Tennessee, Texas, Utah, Washington
Drug(s) in Trial Other Drug Names Main Known Action
FPA150anti-B7-H4 monoclonal antibody FPA150blocks B7-H4 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03363776I/IIaAdvanced solid tumorsPhase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial TumorsView DrugsArizona, California, Massachusetts, New York, South Dakota
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986277Undisclosed mechanism
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03110107I/IIaAdvanced solid tumorsPhase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsMassachusetts, New Jersey, New York, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986218Blocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02913313I/IIaAdvanced solid tumorsPhase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsNew Jersey, New York, Pennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986207anti-TIGIT monoclonal antibody BMS-986207Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02754141I/IIaAdvanced solid tumorsA Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid TumorsView DrugsMaryland, Massachusetts, New York, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986179anti-CD73 monoclonal antibody BMS-986179Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03872206I/IIaPlatinum resistant or refractory mesothelin+ ovarian cancer (inc ovarian expansion)A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available TherapyView DrugsTennessee
Drug(s) in Trial Other Drug Names Main Known Action
HPN536HPN536 - a T cell engaging, mesothelin/CD3-specific TriTACdirects T cells to kill mesothelin-expressing cancer cells
NCT03829501I/IIAdvanced solid tumorsA Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesView DrugsConnecticut, Florida, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
KY1044Stimulates ICOS to increase T cell activity and immune response
NCT03907852I/IIAdvanced mesothelin+ solid tumors (inc ovarian expansion)A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing CancerView DrugsTennessee
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
TC-210 T cellsImmune response against cancer expressing mesothelin
NCT02068794I/IIPlatinum resistant or refractory ovarian cancerPhase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian CancerView DrugsMinnesota
Drug(s) in Trial Other Drug Names Main Known Action
MV-NISoncolytic measles virus encoding thyroidal sodium iodide symporterInduces immune response and tumor cell lysis
NCT02904226I/IIAdvanced solid tumorsPhase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor MalignanciesView DrugsCalifornia, Colorado, Connecticut, District of Columbia, Illinois, Massachusetts, Missouri, New Jersey, New York, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
JTX-2011ICOS agonist monoclonal antibodyStimulates ICOS to increase T cell activity and immune response
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02671435I/IIAdvanced solid tumorsA Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid TumorsView DrugsAlabama, Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Washington
Drug(s) in Trial Other Drug Names Main Known Action
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonist
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
MonalizumabIPH2201, anti-NKG2A monoclonal antibody IPH2201Blocks HLA-E inhibition of NKG2A+ NK and cytotoxic T-lymphocytes
NCT02762981I/IIAdvanced solid tumorsPhase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid TumorsView DrugsArizona, California, Illinois
Drug(s) in Trial Other Drug Names Main Known Action
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitor
RelacorilantCORT125134GR antagonist
NCT02487095I/IIExtrapulmonary small cell ovarian cancerA Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell CancersView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
BerzosertibVX-970, M6620, VE-822, ATR kinase inhibitor VX-970ATR kinase inhibitor
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitor
NCT02484404I/IIRecurrent ovarian cancerPhase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03029598I/IIPlatinum resistant ovarian cancer (at least 1 non-platinum therapy)Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerView DrugsWashington
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02953457I/IIRecurrent, persistent or refractory high grade serous BRCA1/2-mutated ovarian cancerA Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 MutationView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02963831I/IIPlatinum resistant or refractory ovarian cancer (with peritoneal disease)A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal MalignanciesView DrugsFlorida, New York, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
ONCOS-102CGTG-102, Ad5/3-D24-GMCSF, GM-CSF-encoding oncolytic adenovirus CGTG-102Anti-tumor immune response
NCT03013491I/IIAdvanced solid tumorsAn Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or LymphomasView DrugsCalifornia, Connecticut, Illinois, Indiana, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee, Texas, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CX-072Blocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
VemurafenibRO5185426, PLX4032, ZelborafBRAF kinase inhibitor
NCT03162627I/IIRecurrent ovarian cancer with Ras pathway alterations or PARP inhibitor resistanceEvaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP ResistanceView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
SelumetinibAZD6244, ARRY-142886MEK inhibitor
NCT02587962I/IIAdvanced solid tumorsA Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid TumorsView DrugsCalifornia, Maryland, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BirinapantSmac Mimetic TL32711, TL32711SMAC mimetic and IAP antagonist
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03251924I/IIAdvanced solid tumorsA Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsView DrugsMassachusetts, New Jersey, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986226anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226Stimulates ICOS to increase T cell activity and immune response
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03157128I/IIAdvanced solid tumorsA Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)View DrugsArizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
LOXO-292RET kinase inhibitor LOXO-292RET-kinase inhibitor
NCT03602079I/IIAdvanced HER2+ solid tumorsA Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved TherapiesView DrugsFlorida, Massachusetts, Michigan, New York, Oklahoma, Oregon, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
A166anti-HER2 antibody-drug conjugate A166ADC: anti-HER2 + cytotoxic agent
NCT03665285I/IIAdvanced solid tumorsA Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsView DrugsCalifornia, Connecticut, New Jersey, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
NC318
NCT03446040I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant TumorsView DrugsCalifornia, Colorado, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986258anti-TIM3 antibody BMS-986258Blocks TIM-3 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03721679I/IIAdvanced solid cancersPoly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot StudyView DrugsMaryland, New York
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
poly ICLCpoly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLCActivates dendritic cells and induces interferon production
NCT03678883I/IIAdvanced solid tumorsPhase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid TumorsView DrugsCalifornia, Florida, Minnesota, Rhode Island
Drug(s) in Trial Other Drug Names Main Known Action
9-ING-41Downregulates NF-kappaB
CarboplatinParaplatin, NovoplatinumDNA damaging agent
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitor
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
LomustineGleostine, CCNUDNA damaging agent
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03775850I/IIAdvanced MSI-high solid tumors that relapsed following PD-1/L-1 checkpoint inhibitor therapyA Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsView DrugsFlorida, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
EDP1503monoclonal microbial EDP1503
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03761914I/IIRecurrent or persistent WT1+ ovarian cancerA Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced CancersView DrugsCalifornia, Florida
Drug(s) in Trial Other Drug Names Main Known Action
Galinpepimut-SImmune response against cancer expressing WT1
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03729596I/IIAdvanced solid tumorsA Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid TumorsView DrugsMichigan, North Carolina, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
MGC018A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payloadADC: anti-B7-H3 + DNA alkylating agent (Duocarmycin)
NCT03744468I/IIAdvanced solid tumorsPhase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid TumorsView DrugsColorado, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
BGB-A425Blocks TIM-3 inhibition of T cells
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cells
NCT03637764I/IIPlatinum resistant or refractory ovarian cancer (no prior therapies for resistant/refractory disease)A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced MalignanciesView DrugsCalifornia, Massachusetts, New Jersey, New York, Pennsylvania, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
Isatuximabanti-CD38 monoclonal antibody SAR650984Blocks CD38 and stimulates anti-tumor immune response
NCT03767348I/IIAdvanced solid tumor (with at least one injectable tumor)An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsView DrugsMiami
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RP1oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virusInduces immune response and tumor cell lysis
NCT03843775I/IIAdvanced solid tumors with activating non-V600 BRAF mutationsA Phase I/II Study of Binimetinib With Encorafenib in Patients With Non-V600 Activating BRAF Mutant Advanced MalignanciesView DrugsNew Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action
BinimetinibARRY-438162, ARRY-162, MEK inhibitor MEK162, MEK162MEK inhibitor
EncorafenibRaf Kinase Inhibitor LGX818, LGX818RAF inhibitor
NCT02988817I/IIAdvanced solid tumorsFirst-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax®-AXL-ADC) in Patients With Solid TumorsView DrugsArizona, Colorado, Connecticut, Florida, Georgia, Iowa, Massachusetts, Michigan, Minnesota, New York, North Carolina, Pennsylvania, Texas, Utah, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
HuMax-AXL-ADCanti-AXL monoclonal antibody-MMAE conjugate, anti-AXL/MMAE antibody-drug conjugateADC: anti-Axl + microtubule destabilizer (MMAE)
NCT03564340I/IIPlatinum resistant or refractory ovarian cancerA Phase 1/2 Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian CancerView DrugsMassachusetts, New York, Ohio, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
Cemiplimabanti-PD-1 monoclonal antibody REGN2810, anti-PD-1 monoclonal antibody REGN2810Blocks PD-L1/2 inhibition of T cells
REGN4018Immune response against cancer expressing MUC16 (CA125)
NCT03459222I/IIAdvanced solid tumorsA Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsView DrugsCalifornia, Colorado, Maryland, Missouri, Tennessee, Washington
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986205Inhibits IDO1 to stimulate immune response
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RelatlimabBMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016Blocks LAG-3 inhibition of T cells
NCT03407976I/IIAdvanced solid tumors with high MSI or dMMRA Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)View DrugsUtah
Drug(s) in Trial Other Drug Names Main Known Action
ApatinibYN968D1, Aitan, ATAN, Rivoceranibc-Met/VEGFR2 kinase inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03314935I/IIAdvanced solid tumorsA Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid TumorsView DrugsAlabama, California, Georgia, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
INCB001158CB-1158, Arginase inhibitorArginase inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03149549I/IIAdvanced solid tumors (inc expansion)A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)View DrugsCalifornia, Connecticut, Illinois, Indiana, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CX-2009anti-CD166 probody-drug conjugate CX-2009, PDC CX-2009, anti-CD166-DM4 CX-2009, ADC CX-2009ADC: anti-CD166 + microtubule destabilizer (DM4)
NCT03435640I/IIAdvanced solid tumorsA Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor MalignanciesView DrugsArizona, Connecticut, Florida, Georgia, New York, North Carolina, Oregon, Texas
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NKTR-214IL-2 receptor agonist
NKTR-262TLR7/8 agonist and immune cell activator
NCT03400332I/IIAdvanced solid tumorsA Phase 1/2a Study of BMS-986253 in Combination With Nivolumab in Advanced CancersView DrugsColorado, Florida, Maryland, Michigan, Nevada, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, South Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986253IL-8 antagonist
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03345485I/IIAdvanced solid tumorsA Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid TumorsView DrugsCalifornia, District of Columbia, Illinois, Michigan, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
TinostamustineEDO-S101HDAC inhibitor
NCT03369223I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsColorado, Florida, Maryland, New Jersey, New York, Oregon, Pennsylvania, South Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986249Probody of ipilumumabBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03386526I/IIAdvanced solid tumorsA Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic MalignanciesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
APG-138SM-138SMAC mimetic and IAP antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03549000I/IbAdvanced solid tumors (inc expansion)A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.View DrugsFlorida, Texas
Drug(s) in Trial Other Drug Names Main Known Action
NIR178adenosine A2A receptor antagonist NIR178Blocks adenosine A2A receptor inhibition of T cells
NZV930SRF373Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells
Spartalizumabanti-PD-1 monoclonal antibody PDR001Blocks PD-L1/2 inhibition of T cells
NCT03811652I/IbAdvanced solid ASCT2+ (glutamine transporter) tumorsA Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid TumorsView DrugsNorth Carolina, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
MEDI7247antibody-drug conjugate MEDI7247ADC: anti-ASCT2 + DNA damaging agent (PBD dimers)
NCT03061188I/IbAdvanced solid tumors (inc expansion--ATR, ATM, CHEK1/2, BRCA1/2, BAP1, BARD1, FANCA/C/D2/E, RAD50/51, PALB2, CDK12, POLE, POLD1, PRKDC, ERCC2, POLQ, MRE11A, NBN mutations or FANCA/C/D2/E or EMSY amplification)Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair GenesView DrugsIllinois
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
VeliparibABT-888PARP inhibitor
NCT02219711I/IbAdvanced solid tumors with MET, AXL, RET, TRK, DDR2, KDR, PDGFRA or KIT alterations (in expansion)A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor MalignanciesView DrugsCalifornia, Colorado, Florida, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Nebraska, New York, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
SitravatinibMGCD516, multitargeted kinase inhibitor MGCD516Multi-targeted RTK inhibitor
NCT03884556I/IbAdvanced solid tumors (inc expansion)Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor MalignanciesView DrugsFlorida, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
TTX-030anti-CD39 monoclonal antibodyInhibits the breakdown of ATP by CD39
NCT03628677IAdvanced solid tumors (inc expansion)A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesView DrugsNorth Carolina, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AB122Blocks PD-L1 inhibition of T cells
AB154Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
NCT03889275IAdvanced solid tumors (inc expansion)An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid TumorsView DrugsArizona, California, Minnesota, New York, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
MEDI5395Induces immune response and tumor cell lysis
NCT03894540IAdvanced solid tumors (inc expansion)A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid TumoursView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
IPN60090Undisclosed mechanism
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03893955IAdvanced solid tumorsA Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid TumorsView DrugsAlabama, California, Connecticut, North Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
ABBV-368Stimulates OX40 to increase T cell activation and immune response
ABBV-927anti-CD40 agonist monoclonal antibody ABBV-927Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response
NCT03715504IAdvanced solid tumorsA Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid TumorsView DrugsMassachusetts, Texas, Utah, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
TP-3654PIM1 inhibitor
NCT03166631IAdvanced solid tumors (inc expansion)An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic MalignanciesView DrugsFlorida, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
BI 754091anti-PD-1 monoclonal antibody BI 754091Blocks PD-L1/2 inhibition of T cells
BI 891065SMAC mimetic BI 891065SMAC mimetic and IAP antagonist
NCT02990481IAdvanced solid tumors (in expansion)A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid TumorsView DrugsArizona
Drug(s) in Trial Other Drug Names Main Known Action
TRK-950monoclonal antibody TRK-950Undisclosed mechanism
NCT03217253IAdvanced solid tumorsA Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic DysfunctionView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
Tazemetostathistone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438EZH2 histone methyltransferase inhibitor
NCT03875287IAdvanced solid tumorsA Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid TumorsView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
ASTX727CDA inhibitor E7727/decitabine combination agent ASTX727DNA methylation inhibitor
NCT03834662IAdvanced solid tumorsA Phase 1 Cohort Dose-Escalation Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients With Advanced or Metastatic Solid Tumor MalignanciesView DrugsMichigan, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AVID200TGFbeta ligand trap
NCT03132922IAdvanced MAGE-A4+, HLA-A1+ solid tumorsPhase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive TumorsView DrugsFlorida, Missouri, New York, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
MAGE-A4ᶜ¹º³²TMAGE-A4 SPEAR, engineered T-cells targeting melanoma-associated antigen-A4 (MAGE-A4)Immune response against cancer expressing MAGE-A4
NCT03834948IAdvanced solid tumors (inc expansion)A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of AO-176View DrugsCalifornia, Oregon, Tennessee, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
AO-176Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis
NCT02152943IAdvanced ER+ and HER2+ solid tumors (in expansion)Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming ResistanceView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
EverolimusZortress, RAD001, Certican, AfinitormTOR inhibitor
LetrozoleFemaraAromatase inhibitor
TrastuzumabHER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, HerceptinHER2 antagonist
NCT00585195IAdvanced solid tumorsPhase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A c-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced CancerView DrugsVermont
Drug(s) in Trial Other Drug Names Main Known Action
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitor
NCT01877382IAdvanced solid tumors that are TP53 WT (in expansion)A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or LymphomasView DrugsMichigan, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
DS-3032bMDM2 inhibitor
NCT01434316IAdvanced solid tumors including those with BRCA mutations (in expansion)Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
DinaciclibSCH 727965, CDK inhibitor SCH 727965CDK1, 2, 5, 9 inhibitor
VeliparibABT-888PARP inhibitor
NCT01582191IAdvanced solid tumorsA Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
EverolimusZortress, RAD001, Certican, AfinitormTOR inhibitor
VandetanibAZD6474, Zactima, ZD6474VEGFR, EGFR, and RET kinase inhibitor
NCT01591356IAdvanced EphA2+ solid tumors (in expansion)EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical TrialView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
siRNA-EphA2-DOPCEphA2 inhibitor
NCT02503709IAdvanced solid tumorsA Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid TumorsView DrugsDistrict of Columbia, Maryland, Massachusetts, Ohio
Drug(s) in Trial Other Drug Names Main Known Action
AT13387Hsp90 inhibitor AT13387Hsp90 inhibitor
AT7519CDKI AT7519, cyclin-dependent kinase inhibitor AT7519CDK1, 2, 4, 6, 9 inhibitor
NCT01351103IAdvanced solid tumors dependent on Wnt ligands (e.g., RNF43 mutations, RSPO fusion); in expansionA Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt LigandsView DrugsCalifornia, Maryland, Massachusetts, Michigan, Texas
Drug(s) in Trial Other Drug Names Main Known Action
LGK974PORCN inhibitor LGK974, porcupine inhibitor WNT974WNT ligand secretion inhibitor
NCT01552434IAdvanced solid tumors (in expansion)A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonist
TemsirolimusCCI-779, ToriselmTOR inhibitor
Valproic acidDepacon, Depakene, Stavzor, ValproateHDAC and NOS inhibitor
NCT02052778IAdvanced solid tumors with FGF/FGFR alterations (in expansion)Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR AberrationsView DrugsArizona, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Michigan, Minnesota, New Mexico, New York, Pennsylvania, South Carolina, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
TAS-120FGFR inhibitor TAS-120FGFR1-4 inhibitor
NCT02389309IAdvanced solid tumorsA Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid TumorsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
DasatinibBMS-354825, SprycelSRC and bcr-abl kinase inhibitor
TemsirolimusCCI-779, ToriselmTOR inhibitor
NCT02503774IAdvanced solid tumors (in expansion)A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid TumorsView DrugsCalifornia, Connecticut, Florida, Georgia, Missouri, North Carolina, Ohio, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
Oleclumabanti-CD73 monoclonal antibody MEDI9447Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells